Timothy Lowinger

Company: Mersana Therapeutics

Job title: Chief Science & Technology Officer

Seminars:

Exploring Learnings From Translational & Clinical Development of Dolaflexin & Dolasynthen ADCs 5:00 pm

Contrasting and sharing pre-clinical and clinical data for Dolaflexin and Dolasynthen ADCs, employing the same payload and same antibody Predicting and evaluating differences in clinical efficacy and tolerability performance based on preclinical data – what are the core lessons? Breaking down how differences in ADC design impact clinical performanceRead more

day: Day One PM